Based on findings from preclinical studies, Arbutus Biopharma (NASDAQ:ABUS) has decided not to advance
AB-452, its first-generation oral hepatitis B-specific RNA
destabilizer, opting instead to continue development of its
next-generation candidate.
In October 2018, it announced a delay in the start of a Phase 1 study to allow more time to characterize the compound.
https://seekingalpha.com/news/3540032-arbutus-bails-on-abminus-452-shares-down-15-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.